Commentary|Articles|November 17, 2026

How Neurocritical Care Pharmacists Are Moving From Reactive to Proactive Roles

Listen
0:00 / 0:00

Salia Farrokh describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.

Salia Farrokh, PharmD, MBA, BCCCP, FNCS, FCCM, a neurocritical care clinical pharmacist specialist at the Johns Hopkins Hospital and associate professor at the Johns Hopkins School of Medicine, recently finished her term as the only pharmacist on the Neurocritical Care Society (NCS) Board of Directors. In this interview, Farrokh describes how the pharmacist’s role in neurocritical care has grown from reactive consultation to proactive leadership in bedside decision-making, multicenter research, protocol development, and interprofessional teaching. She also discusses the challenge of applying evidence from trials that often exclude neurocritical care patients, and why guidelines should account for medications that may not be available worldwide. Farrokh closes with a call for health system leaders to fund a dedicated pharmacist for every intensive care unit (ICU) and to protect time for research, teaching, and policy work to help prevent burnout.

Pharmacy Times: Can you introduce yourself?

Salia Farrokh, PharmD, MBA, BCCCP, FNCS, FCCM: Hi. Well, thanks for having me. My name is Salia Farrokh, I am a neurocritical care clinical pharmacist specialist at the Johns Hopkins Hospital. I've been in this role for about 10 years now, and I am also an associate professor here with the School of Medicine, and I just finished my term as the only pharmacist on the NCS board of directors.

Pharmacy Times: In a recent review on the evolution of neurocritical care pharmacy, what stood out as the biggest shifts in the pharmacist’s role?

Farrokh: That article that we published not that long ago, I think, really gives a good perspective of how far we've come. If you've reviewed that article, it talks about how initially, in the late 1960s, Bob Rapp was asked to run from the pharmacy to the neurosurgery unit to stop IM administration of phenytoin, or intramuscular administration of phenytoin. And that was really the initial spark for him to get more and more involved at the bedside, and he started to use his pharmacy knowledge to dose phenytoin and help with therapeutic drug monitoring of phenytoin. It's such a good example of how we really shifted our profession from focusing on the product to patients.

And I think this is what is very, very evident these days: that pharmacists are so involved in every clinical decision-making. They're present at the bedside. They have a solid and valuable voice for clinical interventions in the unit and with the team.

The second thing, I think, which is also very rewarding to see: in 2018, the NCS standards got published, and they do review and recognize pharmacists as critical team members. And I think that's very important and very rewarding to see because you get formal recognition, and it's something that you worked really hard for, and now you see that it's finally in publication.

And I think the last thing is research. There was a time that pharmacists were not really serving as principal investigators. They were available for questions, but they were not really leading research projects. And now you see that a lot of us are involved in not only helping with research projects but really being the brain behind a lot of the big research projects, designing the trials and being the lead authors on those publications.

Pharmacy Times: How has the neurocritical care pharmacist’s place on the interdisciplinary team changed since you started practicing?

Farrokh: Yeah. I think the biggest thing honestly for me, and this might be different for every pharmacist, but I think a lot of pharmacists can probably kind of resonate with this idea that before, a lot of our work was reactive, meaning you got a question from the provider group or other team members, and then you answered those questions. But now, when I'm with the team in the neurocritical care unit, not only am I answering questions, but I'm also helping my team to get to that best plan for the patient. I ask questions. I talk about the evidence. I help my team kind of move to that best ultimate plan for the patient. I think that's really rewarding, that you're not just reactively answering questions, but you're proactively helping your team with the best plan for the patients.

The other thing that I find very rewarding, and I'm very grateful for the opportunity, and this is a change I think for a lot of us, is that as much as we're involved with patient care, which is our priority, we're also very involved with leadership initiatives in the health system. So, as individuals and as clinicians who see the big picture, who see the clinical struggles, we come up with policy and protocol and guideline development plans that can help kind of change our practices and help promote safe medication administration and therapeutics.

So I remember back in the day, people already had policies and protocols, and they would just send them to us for review or for approval. But now I think things have shifted in a way that I'm the one who is recognizing the problem because I'm so involved, and I come up with ideas for changing our protocols and our guidance, and I'm the one actually getting all the stakeholders in one room and asking for their input to make sure everyone's on the same page. And then we're the ones getting it to the leadership and approving it and implementing it, which I think is very rewarding. And you can see the shift from maybe being involved but not really leading those projects to now being the primary force behind a lot of those big, I think very meaningful, policy changes that are very helpful for safe practices.

And then I think lastly, teaching has also changed. I can tell you that maybe 10, 12 years ago when I first started, it was very normal for us to just focus on teaching pharmacists and pharmacy residents and pharmacy students, and that was, I think, expected. But now it's really teaching the whole group. So we provide teaching for nurses, we provide teaching for our providers. In my practice, I can tell you that the pharmacy group, and I'm the lead on that, has developed a very unique elective for our neurocritical care fellows to actually take this course and learn more about advanced pharmacotherapy. And these are physicians who have trained to be neurocritical care fellows, so they either have a neurology or anesthesiology or emergency medicine background. And it's been really rewarding to see how invested they are in learning and also trusting us to teach them and being open to the idea that this is a multidisciplinary discussion where you can learn from anyone and everyone.

And I think ultimately the biggest shift has been that we've worked so hard to get here, and you can see the level of trust, from maybe initially just being curbsided for questions to now being trusted to be a very crucial member of the team, not just for clinical issues, but for policy, safety initiatives, and also teaching and learning purposes.

Pharmacy Times: Neurocritical care has a relatively limited evidence base. How does that affect pharmacists’ clinical decision-making and research priorities?

Farrokh: Yeah, it's a newer field, I think, and that's not a secret. I think neurocritical care patients are unfortunately underrepresented in a lot of the trials. This can sometimes be a little bit challenging because a lot of the studies that we review and we look at, we see that our patients are excluded. So the question is always, can I apply this evidence to my patients? And how can this help me?

As challenging as it is, I think it's a very unique opportunity because it really helps you with your critical thinking skills. You have to really think about, okay, this is the evidence, but I have to go back to the principles of pharmacology and pharmacokinetics to see if this makes sense for my patients or not. And I think ultimately, there is a lot of trial and error, right? Like we have to kind of try and see if things work or not. And maybe the principles make sense, but when you try it, it doesn't really seem to be working for that specific situation or indication.

But the nice thing is that this, I think, has been one of the reasons for the NCS pharmacy section to form an NCS pharmacy research group. This was actually formed in 2011, and we all recognized that there are limitations. The research is not very inclusive of our patients. So this group has actually been working to collaborate across different institutions. So many of us practicing in different institutions have been collaborating on research projects to publish studies that could help, I think, the whole community.

There are many examples. I'm proud to say there are many publications on anticoagulation reversal, nimodipine administration, and peptic ulcer prophylaxis in our population. So I think as much as it could be considered a limitation, it's also an opportunity for us to work together to hopefully establish some guidance for the neurocritical care community.

I think there's still a lot of work to be done. As great as this has been, a lot of the research has been retrospective, so there are a lot of opportunities to do prospective research and do it in a randomized and controlled setting.

Pharmacy Times: As a pharmacist on the NCS Board of Directors, what perspective do you bring that might otherwise be missing?

Farrokh: I just finished my term, and I was the only pharmacist. And it's really interesting to see that as much as we're collaborative, sometimes it's forgotten that you need the pharmacist involvement. You need the pharmacist contribution. So I've always reminded myself and the group that we need to think about the pharmacy students and the pharmacy residents, and whether this education is applicable to them.

And the other piece, something we forget about, is that the hope and the goal is to benefit neurocritical care patients in the world and not just the US. Not every product is available in every part of the world. So I think as someone who's advocating for neurocritical care patients in the world, as a pharmacist, you're always thinking, "Okay, if this is the guideline recommendation, if this is a product that we're talking about in the guidelines, this may not be applicable to 90% of the world, and what do we think about that?" When we're talking about guideline and protocol development, can we have alternatives for maybe low-income or middle-income countries so that they have the opportunity to benefit from those interventions? And I think that's something unique, because pharmacists are really the experts to be involved in those decisions.

And I think, finally, it's not a surprise that pharmacists are probably a lot more comfortable with operations and just getting things done. If there are therapeutic options that may look good on paper, what are the actual operational steps to make them really usable? So yes, this might be a great idea, but what is the cost? What are the resources that are needed? Is this applicable? And I think having those conversations on the board of directors has been eye-opening for a lot of non-pharmacists on the board.

Pharmacy Times: How has the society’s view of pharmacists changed over the years, and where is there still room to grow?

Farrokh: Yeah, I mean, I think everything that I've talked about so far is my perspective coming from a large academic medical center. I think I've been very lucky to do my training and also practice in a large academic medical center. But I think the reality is that there are institutions that are smaller, that maybe don't have a dedicated neurocritical care pharmacist. I think our hope and our goal is that every ICU, regardless of the specialty (we're focused on neuro), should have a dedicated pharmacist, with hopefully a fair patient-to-pharmacist ratio, so that it's safe for the patients. So I think this hopefully is a reminder to health system leaders that having the budget to dedicate a pharmacist to each ICU is necessary. I think that's how we can provide safe pharmacotherapy interventions and monitoring and all of that.

And I think the second piece is that, as much as I think it's been really rewarding and very exciting to have pharmacists involved in every aspect of care (we talked about rounding, being present in emergencies, being involved in research, being involved in policy development and protocol development), a lot of us are doing this without any dedicated time for the extra activities beyond patient care. And the truth is that burnout is real in health care, and especially in clinical pharmacy.

So I would hope that we don't lose that perspective: yes, it's exciting to be involved, but we also have to make sure that if we want our pharmacists to be involved in every aspect, we're dedicating time for those extracurricular activities, such as research and teaching and policy development, because it's really hard to be that present pharmacist in the unit and take care of all the emergencies but also find the time to do all the other very important and very necessary initiatives. So I think, hopefully, we can reinforce that and advocate for that, and hopefully it becomes not just an ideal-world scenario but a norm and a standard that if you are expecting pharmacists to do all these activities, you are giving them the time to do that, to make sure that their well-being is not impacted by all of that.


Related to this article